how to fill syringe for semaglutide Administer Your Own Injections at Home GLP1 Tips for Beginners: How

The landscape of weight management has expanded with new research shedding light on hormones like GLP-1 (glucagon-like peptide-1) and innovative supplements like Curb by Modere

Semaglutide can reduce the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), study results have revealed

Random-effects models were employed for the pooled analysis, and heterogeneity was evaluated using the I2 statistic

Chronic diseases require continuation strategies, not sudden withdrawal

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

Heather Ferris explains what we currently know.